Payment overview · 2025
General Payments
$71.60
4 reported records · 3 companies
Healthcare provider profile · identity verified
Sherry Elder, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · COLUMBIA, SC · NPI 1255700175
Verified facts
What the public records show
CMS Open Payments records show Sherry Elder, FNP received $71.60 in general payments during 2025 across 4 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 46.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.61 | 46.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.46 | 28.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.53 | 24.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $71.60 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 246 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 25 |
| Gabapentin | Gabapentin | 220 | 24 |
| Potassium Chloride | Potassium Chloride | 217 | 27 |
| Omeprazole | Omeprazole | 185 | 30 |
| Furosemide | Furosemide | 178 | 30 |
| Metformin Hcl | Metformin Hcl | 175 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 21 |
| Tramadol Hcl | Tramadol Hcl | 151 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 148 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 19 |
| Trazodone Hcl | Trazodone Hcl | 137 | 22 |
| Eliquis | Apixaban | 131 | 18 |
| Losartan Potassium | Losartan Potassium | 124 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 15 |
| Lisinopril | Lisinopril | 116 | 20 |
| Mirtazapine | Mirtazapine | 90 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 89 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 82 | 14 |
| Famotidine | Famotidine | 81 | suppressed |
| Levetiracetam | Levetiracetam | 81 | 13 |
| Jardiance | Empagliflozin | 78 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 74 | 11 |
| Donepezil Hcl | Donepezil Hcl | 74 | 12 |
| Januvia | Sitagliptin Phosphate | 74 | suppressed |
| Memantine Hcl | Memantine Hcl | 72 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 13 |
| Nifedipine Er | Nifedipine | 60 | suppressed |
| Risperidone | Risperidone | 55 | suppressed |
| Spironolactone | Spironolactone | 55 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 22 |
| Finasteride | Finasteride | 46 | suppressed |
| Carvedilol | Carvedilol | 45 | suppressed |
| Haloperidol | Haloperidol | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Olanzapine | Olanzapine | 43 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 43 | suppressed |
| Sucralfate | Sucralfate | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Prednisone | Prednisone | 34 | 19 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 29 |
| Simvastatin | Simvastatin | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 11 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 21 |
| Topiramate | Topiramate | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 21 |
| Lorazepam | Lorazepam | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fanapt | Iloperidone | 12 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $71.60 · 4 records | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU, ENTYVIO, KISUNLA, SAPHNELO | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error